SCHEMBL2174619

SCHEMBL2174619

Cc1cc(S(=O)(=O)NC(=O)Nc2nc(-c3ccccc3)c(C)s2)cs1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TASP1 Q9H6P5 1/20 0.55
ALOX5 P09917 1/20 0.53
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
RAB9A P51151 3/20 0.51
LMNA P02545 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
GSTO1 P78417 1/20 0.51
PKM P14618 1/20 0.51
ALDH1A1 P00352 8/20 0.50
HSD17B10 Q99714 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
XIAP P98170 1/20 0.50
CYP1A2 P05177 1/20 0.50
RORC P51449 1/20 0.50
MAPK1 P28482 1/20 0.49
KDM1A O60341 1/20 0.48
MAPT P10636 6/20 0.47
NPC1 O15118 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2174771 0.88 ALDH1A1 (0.53) TASP1MEN1KMT2AALDH1A1HSD17B10
SCHEMBL10810440 0.79 ALOX5 (0.76) ALOX5MEN1KMT2ARAB9ALMNA
SCHEMBL2174983 0.75 FBP1 (0.65) TASP1ALOX5GSTO1ALDH1A1HSD17B10
SCHEMBL2176516 0.75 FBP1 (0.47) TASP1MEN1KMT2AALDH1A1CYP2C9
SCHEMBL2175111 0.74 FBP1 (0.48) TASP1MEN1KMT2ARAB9APKM
SCHEMBL2173961 0.73 FBP1 (0.66) ALOX5ALDH1A1HSD17B10MAPK1
SCHEMBL2174443 0.73 FBP1 (0.47) TASP1
SCHEMBL2174382 0.73 FBP1 (0.57) ALOX5ALDH1A1HSD17B10CYP2C9CYP2C19
SCHEMBL2177646 0.72 FBP1 (0.61) TASP1MEN1KMT2A
SCHEMBL15086878 0.72 ALOX5 (0.74) ALOX5MEN1KMT2ARAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973051-B2 Aminothiazoles as FBPase inhibitors for diabetes HOFFMAN-LA ROCHE INC. (US) 2011-07-05 US claimed
EP-2227468-A1 AMINOTHIAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-15 EP claimed
US-20090143448-A1 NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-04 US claimed
WO-2009068467-A1 AMINOTHIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-04 WO claimed
US-7973051-B2 Aminothiazoles as FBPase inhibitors for diabetes HOFFMAN-LA ROCHE INC. (US) 2011-07-05 US disclosed
US-20090143448-A1 NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143448-A1 NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES FBP1, SLC5A1, DPP4 TASP1 52/4885ALOX5 4469/4885MEN1 1402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.